TABLE 3

Separate generalized logit regression models at all study visits to predict clinical outcome group statusa

CharacteristicUnit increasebORc (95% CI)
Return to health vs symptoms onlyReturn to health vs PTLDS
Acute phase, pretreatment
    Fibrinogen443.74 ng/ml0.96 (0.65–1.44)0.78 (0.44–1.36)
    MIG383.42 pg/ml0.91 (0.63–1.31)0.84 (0.35–2.02)
    IP-10509.06 pg/ml0.94 (0.67–1.32)0.85 (0.32–2.28)
    CRPd57,140.56 ng/ml1.02 (0.68–1.53)1.57 (0.88–2.78)
    Serum amyloid A3,173.89 ng/ml1.09 (0.78–1.51)1.11 (0.68–1.79)
    Ferritin81,533.50 pg/ml0.86 (0.55–1.34)0.52 (0.15–1.82)
    CCL1978.81 pg/ml1.27 (0.87–1.85)1.36 (0.75–2.48)
    Age1 yr1.01 (0.97–1.06)0.97 (0.90–1.03)
    SexFemale to male1.16 (0.33–4.15)0.32 (0.03–3.04)
    Erythema migransSingle to disseminated0.98 (0.28–3.36)0.30 (0.03–3.45)
    SerologyNegative to positive1.12 (0.26–4.79)0.82 (0.12–5.67)
Posttreatment follow-up
    CCL1949.96 pg/ml1.49 (0.89–2.48)2.09 (1.12–3.88)e
    Age1 year1.02 (0.98–1.06)0.98 (0.92–1.04)
    SexFemale to male0.96 (0.31–3.03)0.41 (0.06–2.97)
    Presence of EM lesionsSingle to disseminated0.85 (0.27–2.66)0.10 (0.01–1.96)
    SerologyNegative to positive1.32 (0.38–4.60)0.72 (0.13–4.05)
1-mo follow-up
    CCL1951.73 pg/ml1.47 (0.88–2.47)1.90 (1.06–3.39)e
    Age1 year1.01 (0.97–1.05)0.96 (0.90–1.02)
    SexFemale to male1.05 (0.32–3.40)0.33 (0.05–2.26)
    Presence of EM lesionsSingle to disseminated0.86 (0.27–2.69)0.09 (0.01–2.33)
    SerologyNegative to positive1.23 (0.33–4.60)0.48 (0.08–2.72)
3-mo follow-up
    CCL1942.08 pg/ml1.20 (0.81–1.78)1.72 (1.03–2.88)e
    Age1 year1.02 (0.98–1.06)0.98 (0.92–1.04)
    SexFemale to male1.07 (0.34–3.44)0.46 (0.06–3.43)
    Presence of EM lesionsSingle to disseminated0.89 (0.29–2.74)0.18 (0.01–2.24)
    SerologyNegative to positive1.12 (0.32–3.87)0.52 (0.09–2.92)
6 mo posttreatment
    CCL1930.99 pg/ml1.17 (0.82–1.67)1.84 (1.12–3.02)e
    Age1 year1.02 (0.98–1.06)0.97 (0.91–1.03)
    SexFemale to male0.90 (0.29–2.75)0.26 (0.04–1.92)
    Presence of EM lesionsSingle to disseminated0.89 (0.28–2.83)0.10 (0.01–1.40)
    SerologyNegative to positive1.34 (0.40–4.56)0.84 (0.15–4.72)
1 yr posttreatment
    CCL1945.97 pg/ml1.03 (0.56–1.88)2.83 (1.15–6.94)e
    Age1 year1.01 (0.97–1.05)0.98 (0.91–1.04)
    SexFemale to male0.77 (0.24–2.50)0.36 (0.04–3.57)
    Presence of EM lesionsSingle to disseminated1.07 (0.32–3.52)0.18 (0.01–2.30)
    SerologyNegative to positive1.35 (0.37–4.97)1.17 (0.16–8.47)
  • a Clinical outcome group status (PTLDS, symptoms only, and return to health) was defined using a previously published definition incorporating both persistent symptoms and functional impact (25).

  • b For immune markers, a unit increase was set at 0.5 SD for the Lyme disease participant sample.

  • c OR, odds ratio.

  • d CRP, C-reactive protein.

  • e For significance of parameter estimate, P ≤ 0.05.